These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Beyond statins: what to expect from add-on lipid regulating therapy? Laufs U, Weintraub WS, Packard CJ. Eur Heart J; 2013 Sep; 34(34):2660-5. PubMed ID: 23832488 [No Abstract] [Full Text] [Related]
3. Cardiologists like statins-more than patients do. Mitka M. JAMA; 2001 Dec 12; 286(22):2799-800. PubMed ID: 11735736 [No Abstract] [Full Text] [Related]
4. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Colhoun H. Lancet; 2005 Nov 26; 366(9500):1829-31. PubMed ID: 16310536 [No Abstract] [Full Text] [Related]
5. Additional insights on how best to utilize statins. Feeman WE. J Fam Pract; 2014 Mar 26; 63(3):128. PubMed ID: 24701605 [No Abstract] [Full Text] [Related]
6. Statins in liver disease: not only prevention of cardiovascular events. Magan-Fernandez A, Rizzo M, Montalto G, Marchesini G. Expert Rev Gastroenterol Hepatol; 2018 Aug 26; 12(8):743-744. PubMed ID: 29768950 [No Abstract] [Full Text] [Related]
7. Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis. Dykun I, Mincu R, Hendricks S, Balcer B, Totzeck M, Rassaf T, Mahabadi AA. Eur J Prev Cardiol; 2020 Oct 26; 27(15):1675-1678. PubMed ID: 31357886 [No Abstract] [Full Text] [Related]
16. Dementia and statins. Lowe G, Rumley A, Packard C, Shepherd J. Lancet; 2001 Mar 17; 357(9259):881. PubMed ID: 11265975 [No Abstract] [Full Text] [Related]
17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ, Watson KE, Talbert RL. J Manag Care Pharm; 2008 Oct 17; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [Abstract] [Full Text] [Related]
18. Fibrates in CVD: a step towards personalised medicine. Staels B. Lancet; 2010 May 29; 375(9729):1847-8. PubMed ID: 20510999 [No Abstract] [Full Text] [Related]